Cargando…
O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies
[Image: see text] Neurodegenerative proteinopathies are characterized by the intracellular formation of insoluble and toxic protein aggregates in the brain that are closely linked to disease progression. In Alzheimer’s disease and in rare tauopathies, aggregation of the microtubule-associated tau pr...
Autores principales: | Permanne, Bruno, Sand, Astrid, Ousson, Solenne, Nény, Maud, Hantson, Jennifer, Schubert, Ryan, Wiessner, Christoph, Quattropani, Anna, Beher, Dirk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026285/ https://www.ncbi.nlm.nih.gov/pubmed/35357812 http://dx.doi.org/10.1021/acschemneuro.2c00057 |
Ejemplares similares
-
Novel non-carbohydrate O-GlcNAcase inhibitors with CNS drug properties as potential treatment for Alzheimer’s disease and tauopathies
por: Hering, Heike, et al.
Publicado: (2013) -
Structural and functional insight into human O-GlcNAcase
por: Roth, Christian, et al.
Publicado: (2017) -
O-GlcNAcase contributes to cognitive function in Drosophila
por: Muha, Villo, et al.
Publicado: (2020) -
Differential Effects of an O-GlcNAcase Inhibitor on Tau Phosphorylation
por: Yu, Yang, et al.
Publicado: (2012) -
Synergy of Peptide and Sugar in O-GlcNAcase Substrate Recognition
por: Schimpl, Marianne, et al.
Publicado: (2012)